Compare Stocks: ZLAB, MDGL, IBRX, and BMRN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$56.05 +1.7%	$63.19	$49.26 ▼ $70.98	$10.67B	0.22	2.29 million shs	2.92 million shs
IBRX ImmunityBio	$10.00 +0.9%	$8.54	$1.95 ▼ $12.43	$10.50B	0.02	15.85 million shs	19.88 million shs
MDGL Madrigal Pharmaceuticals	$459.81 0.0%	$516.27	$393.61 ▼ $615.00	$10.63B	-1.04	278,082 shs	266,163 shs
ZLAB Zai Lab	$23.51 +4.5%	$25.39	$15.96 ▼ $30.00	$2.56B	0.73	781,317 shs	823,985 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	+1.65%	+2.11%	-13.03%	-5.94%	+5.58%
IBRX ImmunityBio	+0.91%	+0.91%	+22.85%	+30.21%	+287.60%
MDGL Madrigal Pharmaceuticals	-0.04%	-3.59%	-12.13%	-16.92%	+6.08%
ZLAB Zai Lab	+4.49%	-5.24%	-5.20%	+16.39%	-20.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$56.05 +1.7%	$63.19	$49.26 ▼ $70.98	$10.67B	0.22	2.29 million shs	2.92 million shs
IBRX ImmunityBio	$10.00 +0.9%	$8.54	$1.95 ▼ $12.43	$10.50B	0.02	15.85 million shs	19.88 million shs
MDGL Madrigal Pharmaceuticals	$459.81 0.0%	$516.27	$393.61 ▼ $615.00	$10.63B	-1.04	278,082 shs	266,163 shs
ZLAB Zai Lab	$23.51 +4.5%	$25.39	$15.96 ▼ $30.00	$2.56B	0.73	781,317 shs	823,985 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	+1.65%	+2.11%	-13.03%	-5.94%	+5.58%
IBRX ImmunityBio	+0.91%	+0.91%	+22.85%	+30.21%	+287.60%
MDGL Madrigal Pharmaceuticals	-0.04%	-3.59%	-12.13%	-16.92%	+6.08%
ZLAB Zai Lab	+4.49%	-5.24%	-5.20%	+16.39%	-20.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.75	Moderate Buy	$88.87	58.55% Upside
IBRX ImmunityBio	2.71	Moderate Buy	$16.00	60.00% Upside
MDGL Madrigal Pharmaceuticals	2.78	Moderate Buy	$699.20	52.06% Upside
ZLAB Zai Lab	2.71	Moderate Buy	$37.25	58.44% Upside

Current Analyst Ratings Breakdown

Latest ZLAB, MDGL, IBRX, and BMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	BMRN BioMarin Pharmaceutical	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$114.00 ➝ $88.00
10/15/2026	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$15.00
10/14/2026	IBRX ImmunityBio	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$12.00 ➝ $14.00
10/14/2026	IBRX ImmunityBio	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$16.00
10/14/2026	MDGL Madrigal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$735.00
10/14/2026	BMRN BioMarin Pharmaceutical	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$111.00 ➝ $114.00
10/12/2026	BMRN BioMarin Pharmaceutical	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Outperform ➝ Strong-Buy	$109.00
10/6/2026	IBRX ImmunityBio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/6/2026	ZLAB Zai Lab	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/25/2026	IBRX ImmunityBio	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/24/2026	MDGL Madrigal Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$704.00

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$3.22B	3.37	$2.90 per share	19.33	$31.68 per share	1.77
IBRX ImmunityBio	$113.29M	93.55	N/A	N/A	($0.51) per share	-19.61
MDGL Madrigal Pharmaceuticals	$958.40M	11.08	N/A	N/A	$26.54 per share	17.33
ZLAB Zai Lab	$460.16M	5.81	N/A	N/A	$6.39 per share	3.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	32.82	10.34	0.38	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
IBRX ImmunityBio	-$351.40M	-$0.97	N/A	N/A	N/A	-598.55%	N/A	-51.65%	11/3/2026 (Estimated)
MDGL Madrigal Pharmaceuticals	-$288.28M	-$12.89	N/A	82.85	N/A	-25.32%	-56.65%	-25.53%	11/3/2026 (Estimated)
ZLAB Zai Lab	-$175.54M	-$1.71	N/A	N/A	N/A	-41.86%	-27.43%	-16.72%	11/5/2026 (Estimated)

Latest ZLAB, MDGL, IBRX, and BMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	ZLAB Zai Lab	-$0.5642	N/A	N/A	N/A	$108.84 million	N/A
11/3/2026	Q3 2026	IBRX ImmunityBio	-$0.07	N/A	N/A	N/A	$59.23 million	N/A
11/3/2026	Q3 2026	MDGL Madrigal Pharmaceuticals	-$0.8345	N/A	N/A	N/A	$405.27 million	N/A
10/26/2026	Q3 2026	BMRN BioMarin Pharmaceutical	$1.35	N/A	N/A	N/A	$1.02 billion	N/A
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/6/2026	Q2 2026	ZLAB Zai Lab	-$0.6794	-$0.46	+$0.2194	-$0.50	$103.87 million	$106.31 million
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	-$0.22	-$0.14	-$0.22	$49.70 million	$51.24 million
7/30/2026	Q2 2026	MDGL Madrigal Pharmaceuticals	-$2.68	-$1.99	+$0.69	-$1.99	$352.13 million	$364.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
IBRX ImmunityBio	N/A	5.72	5.70
MDGL Madrigal Pharmaceuticals	0.65	3.20	2.94
ZLAB Zai Lab	N/A	2.13	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
IBRX ImmunityBio	8.58%
MDGL Madrigal Pharmaceuticals	98.50%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.68%
IBRX ImmunityBio	66.10%
MDGL Madrigal Pharmaceuticals	17.60%
ZLAB Zai Lab	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
IBRX ImmunityBio	691	1.06 billion	359.28 million	Optionable
MDGL Madrigal Pharmaceuticals	915	23.10 million	19.04 million	Optionable
ZLAB Zai Lab	1,784	113.78 million	108.23 million	Optionable

ZLAB, MDGL, IBRX, and BMRN Headlines

Recent News About These Companies

Zai Lab stock is due for November 5 results

October 15 at 8:15 PM | ad-hoc-news.deA

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases

October 14 at 7:25 AM | marketscreener.comM

Zai Lab (NASDAQ:ZLAB) Stock Price Down 6.3% - Should You Sell?

October 13 at 1:01 PM | marketbeat.com

Zai Lab stock closed at USD 25.58 before ESMO data

October 7, 2026 | ad-hoc-news.deA

Critical Comparison: Zai Lab (NASDAQ:ZLAB) vs. Anixa Biosciences (NASDAQ:ANIX)

October 7, 2026 | americanbankingnews.com

Zai Lab stock faces a key ESMO test after Cantor target call

October 7, 2026 | ad-hoc-news.deA

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Here's Why

October 6, 2026 | marketbeat.com

Is Zai Lab (ZLAB) Cheap After Its ESMO 2026 Lung Cancer Data Update?

October 4, 2026 | finance.yahoo.com

Zai Lab (NASDAQ:ZLAB) Stock Price Down 4.6% - Here's Why

October 2, 2026 | marketbeat.com

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

September 29, 2026 | marketscreener.comM

Zai Lab (NASDAQ:ZLAB) Stock Jumps 3.8% - What's Next?

September 28, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Stock Rating Raised to "Hold" at Wall Street Zen

September 26, 2026 | marketbeat.com

Zai Lab Ltd (ZLAB)

September 24, 2026 | in.investing.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by Brokerages

September 23, 2026 | marketbeat.com

Zai Lab Limited (ZLAB)

September 11, 2026 | finance.yahoo.com

Z.ai shares surge 8% after releasing new AI model running only on Chinese chips

August 26, 2026 | cnbc.com

Zai Lab: Revenue Growth And Zoci's Upside Optionality

August 19, 2026 | seekingalpha.com

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

August 17, 2026 | businesswire.com

Zai Lab (NASDAQ:ZLAB) CFO Sells 619 Shares

August 14, 2026 | insidertrades.com

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Is Zai Lab’s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story?

August 10, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ZLAB, MDGL, IBRX, and BMRN Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

$56.05 +0.91 (+1.65%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$56.64 +0.60 (+1.06%)

As of 04:11 AM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

ImmunityBio NASDAQ:IBRX

$10.00 +0.09 (+0.91%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$10.04 +0.04 (+0.40%)

As of 05:00 AM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$459.81 -0.20 (-0.04%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$460.39 +0.58 (+0.13%)

As of 04:00 AM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Zai Lab NASDAQ:ZLAB

$23.51 +1.01 (+4.49%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$23.73 +0.22 (+0.94%)

As of 04:03 AM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZLAB, MDGL, IBRX, and BMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZLAB, MDGL, IBRX, and BMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZLAB, MDGL, IBRX, and BMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZLAB, MDGL, IBRX, and BMRN Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

ImmunityBio NASDAQ:IBRX

Madrigal Pharmaceuticals NASDAQ:MDGL

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZLAB, MDGL, IBRX, and BMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZLAB, MDGL, IBRX, and BMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZLAB, MDGL, IBRX, and BMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZLAB, MDGL, IBRX, and BMRN Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

ImmunityBio NASDAQ:IBRX

Madrigal Pharmaceuticals NASDAQ:MDGL

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools